<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: Malignant hyperthermia susceptibility genes (&lt;i&gt;RYR1,&amp;nbsp;&lt;/i&gt;&lt;i&gt;CACNA1S&lt;/i&gt;, and&amp;nbsp;&lt;i&gt;STAC3&lt;/i&gt;)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation: Malignant hyperthermia susceptibility genes (
       <i>
        RYR1,
       </i>
       <i>
        CACNA1S
       </i>
       , and
       <i>
        STAC3
       </i>
       )
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation: Malignant hyperthermia susceptibility genes (
        <i>
         RYR1,
        </i>
        <i>
         CACNA1S
        </i>
        , and
        <i>
         STAC3
        </i>
        )
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Henry Rosenberg, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Leslie G Biesecker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Slavotinek, MBBS, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephanie B Jones, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H372130296">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph discusses interpretation and possible interventions following genetic testing for three genes (
         <em>
          RYR1
         </em>
         ,
         <em>
          CACNA1S
         </em>
         , and
         <em>
          STAC3
         </em>
         ) that can cause susceptibility to malignant hyperthermia (MHS).
        </p>
        <p>
         It is not intended to replace clinical judgment in the decision to test or in the care of the individual who was tested. These details are discussed separately in UpToDate [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2189163063">
         <span class="h1">
          HOW TO READ THE REPORT
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype
         </strong>
         – Determine which genes were tested and whether testing involved gene sequencing or evaluating a panel of variants. Gene sequencing should include all coding exons of these three genes. Interrogating only specific variants or subsets of coding exons is considered suboptimal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical correlation
         </strong>
         – Determine whether testing was performed to evaluate a positive personal or family history of malignant hyperthermia (MH)/MHS or for healthy screening, or if the variant was identified as a secondary or incidental finding. Ascertain whether the individual and/or any close relative has had symptoms that could be attributed to MHS and whether they have received a halogenated inhalational anesthetic agent or succinylcholine.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2248453657">
         <span class="h2">
          Personal or family history of MH/MHS and pathogenic or likely pathogenic variant
         </span>
         <span class="headingEndMark">
          —
         </span>
         For an individual with a personal or family history of MH/MHS who has a pathogenic or likely pathogenic variant in the
         <em>
          RYR1
         </em>
         or
         <em>
          CACNA1S
         </em>
         gene, the diagnosis of MHS is confirmed.
        </p>
        <p>
         <em>
          STAC3
         </em>
         -related MHS is inherited in an autosomal recessive pattern, and interpretation of this result requires further testing (such as testing parents). An MHS or genetics expert should be consulted.
        </p>
        <p>
         If testing is performed for a family history of MHS, it is prudent to confirm that the variant identified in the tested individual is the same variant present in the relative with MHS, whenever possible. If such an individual was only tested for variants in one of the three MHS genes or only underwent partial testing of
         <em>
          RYR1
         </em>
         (so-called "hot-spot" sequencing) and testing was negative, further testing is needed. Consultation with an MHS or genetics expert is likely to be helpful. (See
         <a class="local">
          'Resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H134619898">
         <span class="h2">
          Secondary (incidental) finding
         </span>
         <span class="headingEndMark">
          —
         </span>
         If testing was done for healthy screening or evaluation of another condition and the individual is found to have a pathogenic or likely pathogenic variant in
         <em>
          RYR1
         </em>
         or
         <em>
          CACNA1S
         </em>
         , they should be considered to have MHS until proven otherwise.
        </p>
        <p>
         <em>
          STAC3
         </em>
         -related MHS is inherited in an autosomal recessive pattern; interpretation of a pathogenic or likely pathogenic variant in
         <em>
          STAC3
         </em>
         requires further testing.
        </p>
        <p class="headingAnchor" id="H2766252079">
         <span class="h2">
          Variant of uncertain significance (VUS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenicity of many variants in MHS genes remains uncertain. Typically, this is because there is insufficient information to determine whether the variant is associated with MHS or is merely a benign change from the reference sequence. When such a variant is encountered in clinical testing, it is most often classified as a VUS.
        </p>
        <p>
         It can be challenging to make a proper clinical-molecular diagnosis in such individuals; their likelihood of having MHS depends on their pretest probability of disease. They can be treated "as if" they have MHS and can continue to check periodically for information on the variant using a database (such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.emhg.org%2Fdiagnostic-mutations&amp;token=NyRkA1K%2BEfcjom0B%2BqrukqICOJlELRYIzpKDBp9IpgadKu5Id8RZz6O2BpAlfpWf0f0fVUUh8AFcRVokiTGznA%3D%3D&amp;TOPIC_ID=139246" target="_blank">
          EMHG
         </a>
         or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=139246" target="_blank">
          ClinVar
         </a>
         ) or consulting with a genetics or MHS specialist, or they can undergo contracture testing. (See
         <a class="local">
          'Resources'
         </a>
         below and
         <a class="local">
          'Contracture testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2262866316">
         <span class="h1">
          MHS GENETICS AND PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H656340961">
         <span class="h2">
          Inheritance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most MHS is inherited in an autosomal dominant pattern; inheritance of a pathogenic variant in an MHS gene from one parent is sufficient to cause MHS. The family history may fail to show classic autosomal dominant pattern (
         <a class="graphic graphic_figure graphicRef110421" href="/z/d/graphic/110421.html" rel="external">
          figure 1
         </a>
         ), since some relatives may not have been exposed to a halogenated inhalation anesthetic, and not all exposures cause a malignant hyperthermia (MH) event.
        </p>
        <p class="headingAnchor" id="H2279981533">
         <span class="h2">
          Specific genes
         </span>
        </p>
        <p class="headingAnchor" id="H3684367151">
         <span class="h3">
          <i>
           RYR1
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ryanodine receptors (RyRs) are large homotetrameric ion channels that release calcium from intracellular stores during excitation-contraction coupling [
         <a href="#rid2">
          2
         </a>
         ]. There are three tissue-specific genes. The skeletal muscle gene is
         <em>
          RYR1
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Pathogenic variants in
         <em>
          RYR1
         </em>
         are the most common cause of MHS [
         <a href="#rid3">
          3
         </a>
         ]. Hundreds of variants in
         <em>
          RYR1
         </em>
         have been classified, although only a minority are pathogenic or likely pathogenic. From a comprehensive report of 335 variants in
         <em>
          RYR1
         </em>
         , 86 were classified as pathogenic or likely pathogenic, 30 were benign or likely benign, and 219 were variants of uncertain significance (VUS) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         In addition to MHS, some pathogenic variants in
         <em>
          RYR1
         </em>
         can cause exertional rhabdomyolysis, atypical periodic paralyses, and central core disease (CCD), a congenital myopathy associated with hypotonia and weakness [
         <a href="#rid2">
          2
         </a>
         ]. An association with statin myopathy is unclear. Other pathogenic variants in
         <em>
          RYR1
         </em>
         are associated with myopathy inherited in an autosomal recessive pattern. (See
         <a class="local">
          'Myopathy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5161.html" rel="external">
          "Muscle enzymes in the evaluation of neuromuscular diseases", section on 'Periodic paralyses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">
          "Congenital myopathies", section on 'Central core disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2946481866">
         <span class="h3">
          <i>
           CACNA1S
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          CACNA1S
         </em>
         encodes the alpha-1 subunit of the dihydropyridine (DHP) receptor, a skeletal muscle voltage-activated calcium channel upstream of the RyR [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Pathogenic variants in
         <em>
          CACNA1S
         </em>
         can cause MHS, susceptibility to hypokalemic periodic paralysis (hypoKPP), or thyrotoxic periodic paralysis [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3772180327">
         <span class="h3">
          <i>
           STAC3
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          STAC3
         </em>
         encodes a protein that interacts with the alpha-1 subunit of the DHP receptor.
        </p>
        <p>
         Pathogenic variants in
         <em>
          STAC3
         </em>
         can cause MHS as well as
         <em>
          STAC3
         </em>
         -related congenital myopathy (also called Bailey-Bloch congenital myopathy or Native American myopathy [NAM]).
        </p>
        <p class="headingAnchor" id="H1837799956">
         <span class="h2">
          Mechanism of hypermetabolic reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         MH is a hypermetabolic reaction with skeletal muscle rigidity and elevated body temperature due to sustained muscle contraction [
         <a href="#rid3">
          3
         </a>
         ]. It generally requires a triggering exposure (halogenated inhalational anesthetic agent or
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         ).
        </p>
        <p>
         Often the first sign of MH in an anesthetized patient is hypercapnia (increase in end-tidal carbon dioxide [CO
         <sub>
          2
         </sub>
         ]). This is thought to occur due to excessive muscle contraction leading to acidosis. The rapid increase in body temperature and rhabdomyolysis can be fatal if not treated urgently. The exact mechanism(s) by which implicated anesthetics interact with the variant receptors is not well understood.
        </p>
        <p>
         In some individuals, a hypermetabolic state may be induced by increased body temperature or intensive exercise. (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management", section on 'Non-anesthesia-related MH-like episodes'
         </a>
         .)
        </p>
        <p>
         Importantly, not all exposures to a triggering agent in an individual with MHS will necessarily cause MH, and prior reactions or lack of reactions do not predict future reactions.
        </p>
        <p class="headingAnchor" id="H4134427099">
         <span class="h1">
          CLINICAL IMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3516856433">
         <span class="h2">
          Counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant hyperthermia (MH) is a life-threatening condition that can occur when an individual with MHS is exposed to certain volatile anesthetics and
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         (also called suxamethonium). (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management"
         </a>
         .)
        </p>
        <p>
         Individuals with MHS should receive education and counseling of the following (
         <a class="graphic graphic_algorithm graphicRef139931" href="/z/d/graphic/139931.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inform all clinicians providing surgical or anesthesia care about the diagnosis of MHS and that they
         <strong>
          must
         </strong>
         avoid halogenated anesthetic gasses and
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         . (See
         <a class="local">
          'Anesthesia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wear a medic-alert bracelet to make their MHS status visible to any clinicians caring for them. Information is available from MHS organizations. (See
         <a class="local">
          'MHS organizations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Share the diagnosis with all first-degree relatives so they can have the option for testing if desired. (See
         <a class="local">
          'Implications for relatives'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain hydration, especially with exercise; avoid hyperthermia; and be especially careful in hot humid weather. (See
         <a class="local">
          'Myopathy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Individuals with a VUS in an MHS gene should inform all clinicians about their VUS and the possibility that they may have MHS. Other implications depend on the perceived likelihood of MHS.
        </p>
        <p class="headingAnchor" id="H4063880819">
         <span class="h2">
          Contracture testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The in vitro contracture test (IVCT) is performed on a muscle biopsy (typical size, 1.5 to 2 inches) [
         <a href="#rid7">
          7
         </a>
         ]. Testing is definitive if positive, but sensitivity is estimated at only approximately 85 percent. (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management", section on 'Contracture test'
         </a>
         .)
        </p>
        <p>
         This test is only available in a few specialized centers. Because it involves an invasive procedure, it is generally reserved for individuals for whom there is a strong suspicion of MHS (clinical event or strongly positive family history) and for whom a causative genetic variant cannot be identified. It may be performed more commonly in European countries than in the United States.
        </p>
        <p>
         IVCT is rarely performed in individuals with a pathogenic or likely pathogenic variant in an MHS gene on genetic testing or in those who test negative for a known familial pathogenic variant.
        </p>
        <p class="headingAnchor" id="H3864466641">
         <span class="h2">
          Anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         MHS has incomplete penetrance; not all exposures will cause an MH event. Thus, the presence of an MH-like reaction is highly suggestive of MHS, but the absence of a clinical event cannot be used to exclude the possibility of MHS. (See
         <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">
          "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Variable expressivity'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of MH
         </strong>
         – Individuals with a pathogenic variant in an MHS gene and/or a positive contracture test should not be exposed to halogenated inhalational anesthetic agents or
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         (suxamethonium). (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management", section on 'Management of anesthesia in malignant hyperthermia-susceptible patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with possible MHS (based on a history suggestive of MH or diagnosis of MHS in a relative) should follow the same principles until tested.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When receiving any anesthetic, these individuals should have close monitoring of core body temperature, minute ventilation, other vital signs, and end-tidal carbon dioxide (CO
         <sub>
          2
         </sub>
         ), in addition to standard American Society of Anesthesiologists (ASA)-recommended monitoring [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of MH
         </strong>
         – Principle treatments for MH include (see
         <a class="medical medical_review" href="/z/d/html/401.html" rel="external">
          "Malignant hyperthermia: Diagnosis and management of acute crisis"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9322" href="/z/d/drug information/9322.html" rel="external">
          Dantrolene
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Supportive care
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Discontinuation of implicated drug(s)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hyperventilation to correct acidosis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cooling to reduce body temperature
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Treatment of metabolic abnormalities, rhabdomyolysis, and/or arrhythmias as needed
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3070758852">
         <span class="h2">
          Myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some individuals with pathogenic variants in MHS genes may have an exertional myopathy or exertional rhabdomyolysis in addition to MHS. Syndromes are summarized in the table (
         <a class="graphic graphic_table graphicRef65645" href="/z/d/graphic/65645.html" rel="external">
          table 1
         </a>
         ). Myopathies may be apparent early in life (eg, severe scoliosis due to muscle weakness), or may be mild and unappreciated until adulthood. An association with statin-induced myopathy is unclear. (See
         <a class="medical medical_review" href="/z/d/html/16414.html" rel="external">
          "Rhabdomyolysis: Epidemiology and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">
          "Rhabdomyolysis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         These individuals should avoid dehydration, especially during exercise, and should be careful in hot, humid weather due to the risk of nonexertional heat illness (heat stroke). (See
         <a class="medical medical_review" href="/z/d/html/17235.html" rel="external">
          "Exertional heat illness in adolescents and adults: Management and prevention"
         </a>
         .)
        </p>
        <p>
         Early use of an antipyretic for fever is prudent. (See
         <a class="medical medical_review" href="/z/d/html/2734.html" rel="external">
          "Pathophysiology and treatment of fever in adults", section on 'Treatment of fever and hyperpyrexia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H776600920">
         <span class="h1">
          IMPLICATIONS FOR RELATIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         All first-degree relatives of an individual with MHS should be offered testing (termed "cascade testing"). Other relatives may also be candidates for cascade testing (eg, grandchildren, if children are not available). Ideally, the pathogenic variant is first identified in an affected individual, and relatives can be tested for that variant.
        </p>
        <p>
         Genetic testing is generally preferred because it is noninvasive. Results are sufficient for diagnosis if positive or if negative for a known familial variant, with caveats mentioned above. (See
         <a class="local">
          'How to read the report'
         </a>
         above.)
        </p>
        <p>
         Genetic testing can be performed at any age. Unlike hereditary cancer syndromes, where genetic testing carries major implications for prevention and surveillance, MHS is a risk factor for a complication that can occur at any age and is easy to avoid once the diagnosis is established. Some data suggest that the penetrance of MHS (likelihood of a reaction if exposed to a triggering agent) is higher in childhood than in adulthood. Thus, there is not a strong rationale to delay testing until adulthood.
        </p>
        <p class="headingAnchor" id="H1356690739">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H237675978">
         <span class="h2">
          Guidelines and UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines – (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122055.html" rel="external">
          "Society guideline links: Malignant hyperthermia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anesthesia – (See
         <a class="medical medical_review" href="/z/d/html/94576.html" rel="external">
          "Anesthesia for children with myopathy and for children who undergo muscle biopsy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MH susceptibility – (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MH acute management (See
         <a class="medical medical_review" href="/z/d/html/401.html" rel="external">
          "Malignant hyperthermia: Diagnosis and management of acute crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3695163106">
         <span class="h2">
          Genetics experts
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic counselors – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=139246" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical geneticists – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=139246" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3413650960">
         <span class="h2">
          MHS organizations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant hyperthermia association of the United States (MHAUS) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mhaus.org%2Fhealthcare-professionals%2F&amp;token=kKXHxK%2Bt2cji8cnnyYI7JJL30aybUn4dQLkMpmLe%2Bu%2FU2keo9LDjR6MCxwbrZlANxniPLucVEfjvqJXjAkJkSQ%3D%3D&amp;TOPIC_ID=139246" target="_blank">
          https://www.mhaus.org/healthcare-professionals/
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour emergency support from MHAUS – 1-800-MH-HYPER (1-800-644-9737)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         European Malignant Hyperthermia Group –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.emhg.org%2F&amp;token=NyRkA1K%2BEfcjom0B%2BqrukrHwNpJGDSxJQUYhYGfFxw0%3D&amp;TOPIC_ID=139246" target="_blank">
          emhg.org/
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant Hyperthermia Group of Australia and New Zealand (MHANZ) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmalignanthyperthermia.org.au%2Fmalignant-hyperthermia-group-of-australia-and-new-zealand%2F&amp;token=n6GiPrjg6IsV%2BcGg7wFmgCYocXjZaKK4vGZpg2zT0fiLEKm%2BMOZvAWOGLFlXogCnAoVL5Yu2EFn28F29eV9TSIIz9Wmatn8v90zRahQ67lU%3D&amp;TOPIC_ID=139246" target="_blank">
          https://malignanthyperthermia.org.au/malignant-hyperthermia-group-of-australia-and-new-zealand/
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          RYR1
         </em>
         Foundation –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fryr1.org%2F&amp;token=OxKV0xgnZtoBaJsS1SIacEQwgIGIYZ%2BVTHi27FAjuWo%3D&amp;TOPIC_ID=139246" target="_blank">
          ryr1.org/
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2974774835">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dr. Biesecker contributed to this article in his personal capacity. The views expressed are his own and do not necessarily represent the views of the National Institutes of Health or the United States Government.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2010; 2:a003996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston JJ, Dirksen RT, Girard T, et al. Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility. Hum Mol Genet 2022; 31:4087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jurkat-Rott K, Lehmann-Horn F. Muscle channelopathies and critical points in functional and genetic studies. J Clin Invest 2005; 115:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews E, Labrum R, Sweeney MG, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 2009; 72:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang L, Daly C, Miller DM, et al. Permeabilised skeletal muscle reveals mitochondrial deficiency in malignant hyperthermia-susceptible individuals. Br J Anaesth 2019; 122:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urman RD, Rajan N, Belani K, et al. Malignant Hyperthermia-Susceptible Adult Patient and Ambulatory Surgery Center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists Position Statement. Anesth Analg 2019; 129:347.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139246 Version 2.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20961976" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Ryanodine receptors: structure, expression, molecular details, and function in calcium release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19648156" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genetic variation in RYR1 and malignant hyperthermia phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35849058" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16075040" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Muscle channelopathies and critical points in functional and genetic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118277" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30916033" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Permeabilised skeletal muscle reveals mitochondrial deficiency in malignant hyperthermia-susceptible individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31166228" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Malignant Hyperthermia-Susceptible Adult Patient and Ambulatory Surgery Center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists Position Statement.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
